Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...
AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).
AstraZeneca plcAZN announced that the European Commission (EC) has approved a label expansion of its diabetes drug, Forxiga (dapagliflozin). Forxiga has been approved for the treatment of type-1 ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w2pvcl/forxiga_type_2) has announced the addition of the "Global Forxiga ...
In final guidance published 26 June 2013, the UK's National Institute for Health and Clinical Excellence (NICE) recommended dapagliflozin (Forxiga, Bristol-Myers Squibb and Astra Zeneca) for some ...
AstraZeneca plc. AZN announced that the Japanese regulatory authority has granted marketing approval to its SGLT2 inhibitor Forxiga for a new indication — as an oral adjunct treatment to insulin in ...
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced Wednesday that Forxiga has received approval in Japan for Type-1 Diabetes or T1D. The Japanese Ministry of Health, Labour and Welfare or MHLW has ...
Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results